JANX011 Shows B Cell Depletion in Healthy Volunteers

Company Janux Therapeutics Event Type First-in-human Phase 1 data (healthy volunteers) Modality TRBV6-selective T-cell engager Asset JANX011 Target CD19; TRBV6 Disease Area Immune thrombocytopenia; rheumatoid arthritis (planned) Summary Janux reported first human pharmacology for JANX011, a CD19 T-cell engager that recruits TRBV6-positive rather than all…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *